Country: Spain
Sector: Health Care
Website: http://www.rovi.esLaboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Year | Total Dividends |
---|---|
2025 | 0.76 EUR |
July 16, 2025 | 0.7574 |
2024 | 1.10 EUR |
July 10, 2024 | 1.1037 |
2023 | 1.29 EUR |
July 5, 2023 | 1.2938 |
2022 | 0.96 EUR |
July 7, 2022 | 0.9556 |
2021 | 0.38 EUR |
July 7, 2021 | 0.3812 |
2020 | 0.18 EUR |
Nov. 19, 2020 | 0.1751 |
2019 | 0.08 EUR |
July 4, 2019 | 0.0798 |
2018 | 0.12 EUR |
July 5, 2018 | 0.1207 |
2017 | 0.18 EUR |
July 5, 2017 | 0.1830 |
2016 | 0.14 EUR |
June 30, 2016 | 0.1390 |
2015 | 0.17 EUR |
July 2, 2015 | 0.1690 |
2014 | 0.16 EUR |
July 3, 2014 | 0.1612 |
2013 | 0.14 EUR |
July 3, 2013 | 0.1366 |
2012 | 0.13 EUR |
July 4, 2012 | 0.1269 |
2011 | 0.17 EUR |
July 6, 2011 | 0.1721 |
2010 | 0.14 EUR |
July 6, 2010 | 0.1410 |
2009 | 0.09 EUR |
July 8, 2009 | 0.0865 |
2008 | 0.08 EUR |
Sept. 17, 2008 | 0.0783 |
Yearly aggregated dividends
Laboratorios Farmaceuticos Rovi, S.A.
Jul 16, 2025 Paid
Dividend
0.7574 EUR |
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion